From Cuts to Comeback, This Sportswear Icon Is Betting on a Leaner Future

A leading athletic brand is trimming staff to refocus on core categories like running and sneakers.

For investors, the shakeup could signal a turning point if cost discipline translates into margin recovery and renewed market share.

Sharp Shift (Sponsored)

5 Underappreciated Names Gaining Traction

Your portfolio might be doing fine. But why stop at fine when you could aim for game-changing gains?

Our analysts have just released a new special report, highlighting 5 stocks with the potential to double.

These aren’t random picks.

They were hand-selected because they combine:

• Proven fundamentals with long-term staying power

• Technical strength suggesting momentum is building now

Past reports have pinpointed stocks before huge runs of +175%, +498%, even +673%.¹
This exclusive report is yours free—but only until midnight tonight.

[Click here now to download your copy instantly]

Why settle for average when extraordinary is on the table?

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Datadog | DDOG

Price: $136.68

Datadog shares jumped nearly 6% in Thursday’s session, benefiting from positive spillover across the cloud software space after peers like Snowflake and MongoDB posted strong earnings.

With enterprises continuing to invest in AI-driven infrastructure, sentiment toward observability platforms remains upbeat.

Still, volatility is high. Datadog has seen more than a dozen 5% swings in the past year.

The stock remains expensive at over 350x earnings, and investors are wary of whether demand growth justifies the premium.

Analysts note that while the market environment looks supportive, Datadog itself hasn’t yet delivered the same magnitude of upside surprise as some peers.

Why It Matters: For investors seeking exposure to AI-driven enterprise software, Datadog could benefit from sector momentum.

But the valuation and volatility mean timing and risk tolerance are critical.

Hormel Foods | HRL

Price: $25.44

Shares of Hormel are down 20% this year after a tough second quarter. Revenue of $3.03 billion beat expectations, but earnings fell 15% short, and management cut full-year guidance.

Despite its iconic SPAM and Hormel brands, the company faces headwinds from slowing demand and thinner margins.

Still, there were some bright spots. Sales volumes rose 2.7% year-over-year — a welcome reversal after several quarters of declines.

With a dividend yield of 4.6%, Hormel continues to appeal to income-focused investors, even as growth lags peers in the consumer staples sector.

Why It Matters: Hormel’s near-term challenges highlight the limits of pricing power in consumer staples.

Long-term investors may find value in the steady dividend, but sustained earnings growth will depend on successful product innovation and margin recovery.

Sleeper Pick Alert (Sponsored)

Free Report: 5 AI Stocks You Can’t Miss

Bank of America estimates AI’s impact could surpass $15 trillion by 2030. 

That’s a massive wave of opportunity.

Zacks has just released a free report on 5 stocks positioned to capture it.

These aren’t hype plays — they’re real businesses with strong fundamentals and growth potential.

One “sleeper” stock could be the most surprising of all.

The earlier you move, the better your edge.

[Claim your free copy here now]

Biogen | BIIB

Price: $132.22

Biogen shares remain 12% lower year-to-date, but institutional investors are showing renewed interest.

Causeway Capital Management recently boosted its stake by more than 50%, joining other hedge funds that have added exposure.

The support follows a strong Q2, where EPS of $5.47 handily topped estimates and revenue climbed 7% to $2.65 billion.

The biotech remains a story of transition.

While multiple sclerosis drugs still anchor sales, newer treatments for Alzheimer’s and other neurodegenerative conditions could reshape the company’s trajectory.

Analysts are mixed: 11 rate it a Buy, but 21 keep it at Hold, with an average target of $185 versus a ~$133 stock price today.

Why It Matters: Biogen is morphing into more of a value play with optionality on high-profile drug approvals.

For investors comfortable with clinical and regulatory risk, the discount to analyst targets may offer upside.

NetApp | NTAP

Price: $112.79

NetApp reported second-quarter results that topped estimates, sending shares up nearly 5% before settling higher by 3.6%.

Revenue rose modestly to $1.56 billion, while earnings slightly beat consensus at $1.55 per share.

Operating margin expanded to 19.8%, and free cash flow surged to nearly 47% of revenue, a strong sign of underlying efficiency.

The company, a leader in enterprise data storage, is benefiting from steady demand for cloud infrastructure and data management solutions.

With shares up just 1% this year and still trading nearly 12% below their 52-week high, valuation remains reasonable at 21x earnings.

That relative stability stands out in a sector dominated by high-beta names.

Why It Matters: NetApp may not deliver the explosive growth of pure-play cloud peers, but its strong cash generation and improving margins make it a steady way to play digital infrastructure.

Investors seeking balance in a volatile tech space may find it attractive.

Nike | NKE

Price: $77.37

Nike has managed a 6% gain this year, rebounding from last year’s struggles.

The company announced fresh workforce reductions, about 1% of its global corporate staff, as part of CEO Elliott Hill’s push to streamline operations and double down on sports and sneaker culture.

The cuts follow a larger round last year, signaling management’s willingness to make tough decisions.

Financially, Nike is navigating tariffs and supply chain headwinds, but recent results showed resilience.

With revenues stabilizing and a 2% dividend yield, the company is positioning itself to compete more aggressively with Adidas, Puma, and upstart challengers.

Analysts remain divided on whether the stock’s 36x P/E multiple is justified given growth pressures.

Why It Matters: Cost discipline combined with product innovation could set the stage for a brand revival.

Investors may view pullbacks as a chance to build exposure, while monitoring execution risk around the company’s renewed focus on performance categories.

Today’s watchlist highlights both resilience and reinvention.

From a sportswear giant tightening operations to biotech and healthcare names drawing investor attention, and cloud software and storage firms catching AI tailwinds, the market continues to reward clarity and execution.

For investors, blending defensive stability with select growth opportunities remains a prudent way to navigate late-summer volatility.

Stat of the Day – 3.3%

The U.S. economy grew at a 3.3% annualized pace in the second quarter, beating earlier estimates of 3%.

Strong consumer spending and a surge in tech-related investment, particularly in AI infrastructure, drove the revision higher, underscoring resilience despite tariff headwinds.